文献速递腹部技术与安全PETCT

[68Ga]Ga-DOTA-FAPI-04 PET/CT在胰腺癌中的附加价值:与[18F]F-FDG的对比

The added value of [68Ga]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [18F]F-FDG.
PubMed 文献 · Eur Radiol · 2023-02-21

单中心回顾性研究纳入51例胰腺癌患者,比较[68Ga]Ga-DOTA-FAPI-04与[18F]FDG PET/CT的诊断及预后价值。[68Ga]Ga-DOTA-FAPI-04对原发灶、转移性淋巴结和远处转移的敏感度均高于[18F]FDG;[68Ga]Ga-DOTA-FAPI-04的SUVmax>14.9与无进展生存率显著相关,且为PFS的独立预后因素。

要点

  • [68Ga]Ga-DOTA-FAPI-04对原发灶敏感度100% vs [18F]FDG 95.0%。
  • 对转移性淋巴结敏感度96.2% vs 61.5%,对远处转移100% vs 84.0%。
  • [68Ga]Ga-DOTA-FAPI-04 SUVmax>14.9与PFS率显著相关(χ²=12.05,p=0.001)。

核心结论

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT诊断胰腺癌的敏感度和准确率高于[18F]FDG PET/CT,可能具有独立预后价值。

研究设计与样本

  • 单中心回顾性研究,纳入51例接受[68Ga]Ga-DOTA-FAPI-04和[18F]FDG PET/CT的胰腺癌患者,最终诊断经组织病理学或1年随访验证;26例患者纳入Kaplan-Meier生存分析(log-rank检验),多因素分析纳入年龄、性别、分期、CA199水平及两种显像剂SUVmax。

关键影像表现/征象

  • [68Ga]Ga-DOTA-FAPI-04对原发灶敏感度100% vs [18F]FDG 95.0%。
  • 对转移性淋巴结敏感度96.2% vs 61.5%。
  • 对远处转移敏感度100% vs 84.0%(p<0.0001)。
  • [68Ga]Ga-DOTA-FAPI-04肝转移瘤的瘤肝背景比(TLBR)5.7±3.2 vs [18F]FDG 3.2±1.3(p<0.0001)。

诊断标准与关键数值

  • [68Ga]Ga-DOTA-FAPI-04诊断原发灶敏感度100%、转移性淋巴结96.2%、远处转移100%。
  • [18F]FDG诊断原发灶敏感度95.0%、转移性淋巴结61.5%、远处转移84.0%。
  • [68Ga]Ga-DOTA-FAPI-04 SUVmax>14.9与PFS率显著相关(χ²=12.05,p=0.001)。
  • Cox回归显示[68Ga]Ga-DOTA-FAPI-04 SUVmax为PFS独立预后因素(p=0.001;HR=8.877)。

临床应用与阅片要点

  • 原文结论提示[68Ga]Ga-DOTA-FAPI-04 PET/CT诊断胰腺癌的敏感度和准确率高于[18F]FDG PET/CT,可能具有独立预后价值。
  • 化疗前[68Ga]Ga-DOTA-FAPI-04 PET/CT SUVmax>14.9与无进展状态率显著相关(χ²=12.05,p=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We aimed to compare the diagnostic and prognostic performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT in pancreatic cancer.

METHODS: This single-center retrospective study enrolled 51 patients who underwent [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT. The final diagnosis on PET/CT images was verified by histopathology or 1-year follow-up. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT were calculated to compare the diagnostic efficacy. Progression-free survival (PFS) was the endpoint for the survival analysis. Twenty-six patients were eligible for the Kaplan-Meier survival analysis using a log-rank test. And multivariate analysis including age, sex, stage, CA199 level, and SUVmax of [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 was also performed. Two-tailed p < 0.05 was considered statistically significant.

RESULTS: [68Ga]Ga-DOTA-FAPI-04 showed a higher sensitivity than [18F]FDG for detecting primary tumor (100% vs. 95.0%), metastatic lymph nodes (96.2% vs. 61.5%), and distant metastases (100% vs. 84.0%) (p < 0.0001, respectively). For [68Ga]Ga-DOTA-FAPI-04, the tumor-to-liver background ratio (TLBR) of liver metastases was higher (5.7 ± 3.2 vs. 3.2 ± 1.3, p < 0.0001). Furthermore, SUVmax > 14.9 on [68Ga]Ga-DOTA-FAPI-04 was significantly associated with PFS rates (chi-square = 12.05, p = 0.001). The Cox regression analysis showed that SUVmax of [68Ga]Ga-DOTA-FAPI-04 was an independent prognostic factor for PFS (p = 0.001; hazard ratio, 8.877).

CONCLUSIONS: [68Ga]Ga-DOTA-FAPI-04 PET/CT showed a higher sensitivity and accuracy than [18F]FDG PET/CT in diagnosing pancreatic cancer and might have an independent prognostic value for pancreatic cancer patients.

KEY POINTS: • [68Ga]Ga-DOTA-FAPI-04 PET/CT had a higher sensitivity and accuracy in detecting primary tumors, metastatic lymph nodes, and distant metastases than [18F]FDG PET/CT. • SUVmax > 14.9 on [68Ga]Ga-DOTA-FAPI-04 PET/CT before chemotherapy was significantly associated with progress-free status rates (chi-square = 12.05, p = 0.001) in pancreatic cancer patients.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Liu Q, Shi S, Liu S, et al. The added value of [68Ga]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [18F]F-FDG. Eur Radiol. 2023. PMID: 36809431. doi:10.1007/s00330-023-09445-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。